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Objective:  To  evaluate  the effectiveness  of seasonal  inﬂuenza  vaccine  in  preventing  Emergency  Depart-
ment  (ED)  visits  and  hospitalisations  for inﬂuenza  like illness  (ILI)  in  children.eceived in revised form 20 March 2014 Methods:  We conducted  a test negative  case-control  study  during  the  2011–2012  and  2012–2013
ccepted 11 June 2014 inﬂuenza  seasons.  Eleven  paediatric  hospital/wards  in seven  Italian  regions  participated  in the  study.
vailable online 21 June 2014
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Consecutive  children  visiting  the ED  with  an  ILI, as  diagnosed  by  the  doctor  according  to the  Euro-
pean  Centre  for  Disease  Control  case  deﬁnition,  were  eligible  for  the  study.  Data  were  collected  from
trained  pharmacists/physicians  by  interviewing  parents  during  the  ED  visit  (or hospital  admission)  of
their children.  An  inﬂuenza  microbiological  test  (RT-PCR)  was  carried  out  in all children.
∗ Corresponding author. National Centre of Epidemiology, Surveillance and Health Promotion, Italian National Institute of Health, Viale Regina Elena, 299 00161 Rome,
taly.  Tel.: +39 0649904252.
E-mail address: francesca.menniti@iss.it (F. Menniti-Ippolito).
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.048
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Case-control study
Laboratory-conﬁrmed cases
Results:  Seven-hundred  and  four children,  from  6 months  to 16  years of age,  were  enrolled:  262  children
tested  positive  for one  of the  inﬂuenza  viruses  (cases)  and  442  tested  negative  (controls).  Cases  were  older
than  controls  (median  age  46  vs.  29 months),  though  with  a  similar  prevalence  of  chronic  conditions.  Only
25  children  (4%)  were  vaccinated  in  the  study  period.  The  overall  age-adjusted  vaccine  effectiveness  (VE)
was  38%  (95%  conﬁdence  interval  −52%  to 75%).  A  higher  VE  was  estimated  for hospitalised  children  (53%;
95%  conﬁdence  interval  −45%  to 85%).
Discussion:  This  study  supports  the effectiveness  of  the  seasonal  inﬂuenza  vaccine  in preventing  visits  to
the  EDs  and  hospitalisations  for  ILI in  children,  although  the  estimates  were  not  statistically  signiﬁcant
and  with  wide  conﬁdence  intervals.  Future  systematic  reviews  of available  data  will  provide  more  robust
evidence  for recommending  inﬂuenza  vaccination  in children.
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. Introduction
Seasonal inﬂuenza represents an important cause of morbid-
ty and mortality especially for the risk of secondary bacterial
nfections, which is higher in children and elderly than in the
eneral population. The burden of inﬂuenza is highest in young chil-
ren under 5 years of age likely due to immunological immaturity
1–3].
Increasing attack rates during epidemics lead to higher out-
atient visit and hospitalisation rates [3–5]. Inﬂuenza-associated
ospitalisation rates are well described in children with underly-
ng chronic conditions; however accumulating evidence showed
hat the increased risk also affected otherwise healthy children [4].
bservational data indicated that although children with underly-
ng conditions are at higher risk of death, the majority of paediatric
eaths occur among healthy children [6].
The vaccination against inﬂuenza is recognised as an effec-
ive preventive intervention and each country is responsible for
ational programs and for deﬁning targeted risk groups. In the
ajority of European countries, the inﬂuenza vaccine is rec-
mmended for children with underlying medical conditions. UK
uthorities announced plans to extend inﬂuenza vaccination to
ll children aged 2–16 years from 2014 [7]. At present, Finland
s the only European country which has implemented the routine
nﬂuenza vaccination of healthy children (6 months to <3 years) [8].
In Italy, the course of inﬂuenza epidemics generally extends
etween December and April, with a peak in February [9] and
ach year the Ministry of Health promotes a vaccination campaign
etween mid-October and December. The ofﬁcial recommendation
dentiﬁes at risk children as a target group for inﬂuenza vaccina-
ion (provided free of charge); only sub-unit, split or virosomal
easonal vaccine formulations can be administered in children (6
onths to 17 years of age) [10,11]. During the seasons 2011–2012
nd 2012–2013, the composition of the vaccines varied only for
he B virus strain (B/Wisconsin in 2011–2012, and B/Brisbane in
012–2013), whereas the A(H1N1) and A(H3N2) antigens were
resent in both seasons. The two vaccine strains B/Wisconsin and
/Brisbane belong to two different lineages, i.e. B-Yamagata and
-Victoria respectively.
Most of the available evidence on the efﬁcacy and effective-
ess of seasonal inﬂuenza vaccine in a paediatric setting is derived
rom clinical trials and concerns almost entirely healthy children
12–15]. Although these studies adopted heterogeneous outcome
eﬁnitions (e.g. from clinically deﬁned inﬂuenza like-illness (ILI) in
he outpatient setting to laboratory conﬁrmed hospitalisations for
nﬂuenza), they found efﬁcacy estimates of around 70%, higher than
hose on effectiveness (around 40%). Despite the fact that inﬂuenza
accination is primarily recommended in children with underly-
ng conditions, insufﬁcient evidence is available in this population.
oreover, the World Health Organization considers as a target
roup for inﬂuenza immunisation, children from 6 to 23 months,
ven though effectiveness data are scanty [16].hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
The objective of this national study was to determine the
effectiveness of seasonal inﬂuenza vaccination against laboratory-
conﬁrmed inﬂuenza cases visiting the Emergency Department
(hospitalised or not) in a large paediatric population over two
consecutive seasons (2011–2012 and 2012–2013) and to provide
evidence for vaccination recommendations in Italy.
2. Methods
In Italy, since 1999 an active surveillance on drug and vaccine
safety in children has been conducted in various paediatric hospi-
tals/wards located throughout the country [17]. Italian paediatric
hospitals/wards can admit children from 0 to 17 years of age. Over-
all, the network includes 11 sites from seven regions representative
of the whole Country, and around 400,000 children visited the
EDs of the participating centres each year. The network organisa-
tion facilitated the prompt set up of the investigation on inﬂuenza
vaccine effectiveness during the A/H1N1 pandemic (in 2009) and
in two  following inﬂuenza seasons (2011–2012 and 2012–2013).
The results of the A/H1N1 pandemic vaccination campaign were
reported elsewhere [18].
Consecutive children visiting the Emergency Departments (ED)
with an ILI, as diagnosed by the doctor during the ED visit, were
eligible for the study. The ILI case deﬁnition for children was
adapted from the European Centre for Disease Control (ECDC) and
used for inﬂuenza surveillance in Europe since the pandemic sea-
son [19,20]. In detail, the following deﬁnition of ILI was  adopted,
for children >5 years: sudden onset of fever ≥38 ◦C (for at least
24 h), in association with at least one respiratory symptom (cough,
sore throat, coryza), and at least one general symptom (headache,
asthenia, malaise). For children between 6 months and 5 years, in
association with fever >38 ◦C, the following general signs and symp-
toms were considered: inadequate drinking or feeding, vomiting
and/or diarrhoea, respiratory symptoms. All children hospitalised,
or admitted to a Short Stay Unit (up to 24 h observation) were
enrolled, and in some clinical centres also children visiting the ED
but not admitted to hospital were included. Since inﬂuenza vaccine
is indicated for children aged >6 months, younger children were not
eligible.
Written informed consent was  acquired from parents. Data were
collected by trained pharmacists/physicians by interviewing par-
ents during the ED visit (or hospital admission) of their children.
Demographic data, medical history of chronic conditions, date of
vaccination and type of vaccine were collected using a structured
questionnaire. For the assessment of inﬂuenza vaccine effective-
ness, children were deﬁned as vaccinated if they had received at
least one dose more than 14 days before symptom onset.
An inﬂuenza-conﬁrmatory laboratory test was carried out in all
children. The virus was  detected through nasopharyngeal sample
collection; stable viral transport medium was added to swabs. Spec-
imens were collected and analysed by using a real-time reverse
transcriptase-polymerase chain reaction (RT-PCR). In six centres
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he tests were analysed in internal laboratories, whereas the others
ent the specimens to certiﬁed external laboratories.
The ﬁrst phase of the study was performed in the 2011–2012
nﬂuenza season and was  used as a pilot study to reﬁne the
012–2013 investigation. In order to concentrate enrolment and
aboratory tests in the epidemic period the coordinator centre gave
he start-up on the basis of data on inﬂuenza epidemics in Italy
rovided from the National surveillance of ILI incidence [9]. The
nclusion of children took place between 1 February and 31 March
012 (for the 2011–2012 season), and between 14 January and 15
arch 2013 (for the 2012–2013 season). The inclusion periods were
he same for all centres.
Data were analysed according to a test-negative case-control
tudy design: all children with a positive conﬁrmatory laboratory
est (to one of the viruses contained in the seasonal vaccine) were
ncluded as cases, whereas controls were children with a nega-
ive test. For effectiveness evaluation, odds of inﬂuenza vaccination
ere compared in cases and controls.
.1. Study sites
The following paediatric hospitals and departments were par-
icipating: Giannina Gaslini Paediatric Hospital (Genova); Regina
argherita Paediatric Hospital (Torino); Department of Paediatrics,
niversity of Padova; Paediatric Department, Treviso Hospital
Treviso); Anna Meyer Children’s University Hospital (Firenze);
epartment of Paediatrics, University of Perugia; Pharmacology
nd Paediatrics and Developmental Neuroscience, Università Cat-
olica S. Cuore (Roma); Bambino Gesù Paediatric Hospital (Roma);
antobono-Pausilipon Paediatric Hospital-Virologic Unit Cotugno
Napoli); Giovanni Di Cristina Paediatric Hospital (Palermo); Uni-
ersity Hospital of Messina. A common study protocol was
pproved by the Ethics Committee of each clinical centre. The study
as coordinated by the National Centre of Epidemiology of the
ational Institute of Health in Rome.
.2. Statistical analyses
Data were analysed with SPSS (v. 21.0). T-test was used to com-
are means, Wilcoxon–Mann–Whitney non-parametric test was
sed to compare medians and Chi-square test was used to compare
ercentages. Adjusted odds ratios (ORs) and 95% conﬁdence inter-
als (CI) were estimated through a logistic regression model. ORs
ere adjusted for age, which was included in the logistic model
25
13
10
13
3 p
5 p
Pati ents includ ed 
N=70 4 
Eligible patients N=773
Positi ve labo ratory test 
(Cases) 
N=262 
Fig. 1. Flow chart concerning the studyne 32 (2014) 4466–4470
as a continuous variable (in months). We  estimated the seasonal
inﬂuenza vaccine effectiveness (VE) as 1 minus the OR, expressed
as a percentage.
3. Results
Among the 773 eligible children, 69 (9%) were excluded (Fig. 1).
The main reason for exclusion was lack of informed consent either
to collect the nasopharyngeal swab (n = 25) or to be included in
the study (n = 10). The 704 remaining children were classiﬁed as
cases (262 children tested positive for one of the inﬂuenza viruses)
and controls (442 children who tested negative). The percentage
of hospitalised children was 56% (n = 148) among cases and 75%
(n = 332) among controls. Overall, the age of the enrolled children
ranged from 6 months to 16 years.
The proportion of cases ranged from 12% to 56% in the 11 centres.
In 69% of cases and 55% of controls the test was performed the same
day of symptom onset. In 97% of cases and in 93% of controls the test
was carried out within 2 days. Among cases, B virus was  detected
in 126 children (48%), A(H1N1) in 59 (23%), unspeciﬁed A virus in
33 (13%), A(H1N1)pdm09 in 22 (8%) and A(H3N2) in 22 (8%). In the
2012–2013 season the virology unit of one clinical centre was  able
to characterise 40 of the 126 cases positive for inﬂuenza B virus:
they all resulted belonging to B/Yamagata/16/88 lineage.
Cases and controls were similar with regard to gender and
prevalence of chronic diseases, whereas a statistically signiﬁcant
difference was observed for age (46 months in cases and 29 months
in controls) (Table 1).
The median duration of symptoms before the visit to the ED was
similar in the two  groups (3 days vs. 2), as it was the level of fever
(median of 39 ◦C in both groups). According to the ILI deﬁnition all
children presented fever ≥38 ◦C. Cough was  the most frequently
associated symptom in both cases and controls (85% vs. 83%), fol-
lowed by rhinorrhea, malaise, sore throat and asthenia. Vomiting or
diarrhoea were more frequently reported in younger children (40%
in patients up to 5 years and 21% in older ones). Sixty-eight percent
of children were hospitalised through the EDs and the mean dura-
tion of hospitalisation was not statistically different in cases and
controls (3.6 and 4.3 days respectively).
Only 25 children (4%) were vaccinated against inﬂuenza: seven
of the 262 cases and 18 of the 442 controls (they had been vacci-
nated between October and mid-January). The date of vaccination
was not available for six children (one case and ﬁve controls).
However, it is likely that these children were vaccinated at least
 pts: test not perf ormed  
 pts: fever <38° C 
 pts: lack o f con sent  
 pts: discharged b efore interview 
ts: parents not found 
ts: other rea son s 
Pati ents exclud ed  (N=69 ) 
Negati ve labo ratory test 
(Con trols) 
N=442 
 population included in the study.
F. Menniti-Ippolito et al. / Vacci
Table  1
Main characteristics of cases and controls.
Cases Controls p
Number 262 442
Median age, months (IR) 46 (26–71) 29 (15–54) <0.001
%  females 45 47 0.78
Chronic diseases: N. (%) 47(18) 67(15) 0.34
Duration of symptoms
before admission to ED,
median days
3 2 0.01
Symptoms of ILI at admission to ED
Fever, median ◦C 39 39 0.13
Cough, N (%) 224(85) 365(83) 0.31
Rhinorrhea, N (%) 122(47) 217(49) 0.52
Malaise, N (%) 111(42) 166(38) 0.21
Sore throat, N (%) 85(32) 135(31) 0.60
Asthenia, N (%) 62 (24) 88 (20) 0.24
Vomiting, N (%) 58(22) 130(29) 0.04
Diarrhoea, N (%) 27 (10) 76(17) 0.01
Bronchitis, N (%) 22 (8) 73 (17) 0.002
Hospitalisation, N. (%) 148 (56) 332 (75) <0.001
Length of staya (mean,
days)
3.6 4.3 0.20
Type of virus, N (%)
B 126 (48) –
A  (H1N1) 58(23) –
A (unspeciﬁed) 33(13) –
A  (H1N1) pdm09 22 (8) –
A  (H3N2) 22 (8) –
IR: interquartile range, ED: Emergency Department.
a
1
b
c
c
e
(
s
c
v
i
t
d
1
conditions increase the likelihood of developing an ILI and repre-
sent, at the same time, an indication for vaccination. In our study,
T
VAmong hospitalised children.
4 days before hospital admission, since they were hospitalised
etween the end of January and February. Twelve out of the 25 vac-
inated children (46%) reported a chronic disease (asthma, allergy,
ardiomyopathy, spinal muscular atrophy [SMA 1 or 2], immunod-
ﬁciency, aplastic anaemia, coeliac disease, West syndrome).
The overall age-adjusted VE was 38% (95% CI: −52% to 75%)
Table 2). A slightly lower VE was estimated in the 2012–2013 sea-
on (VE 26%; 95% CI: −153% to 78%). Three out of seven vaccinated
hildren were positive to unspeciﬁed A virus (one child) or A/H3N2
irus (two children) in the 2011–2012 season, whereas the remain-
ng four vaccinated cases in the 2012–2013 season were positive
o B virus. Nine children (one case and eight controls) received two
oses of the vaccine in the same season (VE 79%; 95% CI: −57% to
00%).
able 2
accine effectiveness in the two  inﬂuenza seasons.
Inﬂuenza vaccine Cases N (%) Controls N (%) 
Yes 7 (3) 18 (4) 
No  255 (97) 424 (96) 
Total 262 (100) 442 (100) 
Season 2011–2012
Inﬂuenza vaccine Cases N (%) Controls N (%) 
Yes 3 (5) 10 (8) 
No  58 (95) 119 (92) 
Total 61 (100) 129 (100) 
Season 2012–2013
Inﬂuenza vaccine Cases N (%) Controls N (%) 
Yes 4 (2) 8 (3) 
No  197 (98) 305 (97) 
Total  201 (100) 313 (100) 
a Vaccine effectiveness adjusted by age.ne 32 (2014) 4466–4470 4469
When the analysis was restricted to hospitalised children a
higher estimate of VE, with respect to the overall, was  obtained
(53%; 95% CI −45% to 85%).
4. Discussion
Our study estimated around 40% reduction in visits to EDs and
hospitalisations for ILI in children, although not statistically signif-
icant and with wide conﬁdence intervals.
Even though the conﬁdence intervals of the estimates were
largely overlapping, a slightly lower effectiveness was  estimated in
the second year. The four vaccinated cases in the 2012–2013 season
were positive to the B virus. Data from our study and virological
surveys performed in Italy [21] showed that the B/Yamagata lin-
eage was circulating in the latter season (whereas B/Brisbane strain,
belonging to a different lineage, was  included in the seasonal vac-
cine), which may  explain the lower VE of the 2012–2013 vaccine
with respect to the 2011–2012, when the A(H3N2) and A(H1N1)
were mostly present. The matching between the vaccine and circu-
lating strains of inﬂuenza season is a recognised factor inﬂuencing
the VE [22].
The main limitation of the study derives from the low vaccina-
tion coverage observed in the Italian paediatric population (4% in
the control group). This proportion was  similar to that observed in
Italy during the 2009 pandemic [23]. Due to the few vaccinated chil-
dren it was  not possible to perform stratiﬁed analyses by variables
of interest, such as type of virus/vaccine, age groups, presence of
chronic conditions and prior vaccination status. Assuming as true
the estimate of efﬁcacy in our study, to reach statistical signiﬁ-
cance we  should have had (with alpha error of 5% and power 80%),
either a 25% proportion of vaccinated children or a study popu-
lation of ILI larger than 4000. However, the number of children
enrolled in our study is large in comparison with other recently
published articles. In the I-MOVE study, the paediatric population
(1–14 years) amounted to 512 children who  were included in ﬁve
European countries [24].
The adopted study design allows to control for the confounding
effect of baseline clinical status. The reason relies on the deﬁnition
of the control group, consisting of children who tested negative for
the inﬂuenza virus vaccine [25]. It is well documented that severalcase and control subjects were similar with reference to the preva-
lence of chronic conditions, but not for symptoms at onset. For
Total Crude OR (95% CI) Adj VEa (95% CI)
25 35% (−65% to 77%) 38% (−52% to 75%)
679
704
Total Crude OR (95% CI) Adj VEa (95% CI)
13 38% (−152% to 89%) 41% (−126% to 84%)
177
190
Total Crude OR (95% CI) Adj VEa (95% CI)
12 23% (−194% to 83%) 26% (−153 to 78%)
502
514
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nstance, vomiting and diarrhoea were more frequent in controls.
hese symptoms are more often associated with ILI presentation in
ounger children. The age difference is in line with that observed
n other European countries. In the I-MOVE study, the difference in
he mean age between cases and controls in the paediatric popula-
ion (1–14 years) was 1.5 years, similar to the difference observed
n our study [24].
Almost all nasopharyngeal swabs were carried out within 2
ays from symptoms onset to the ED, which is associated with a
reater speciﬁcity. The fact that results were obtained several days
fter having conducted the test, excludes the possibility that the
xposure information may  have been biased by the knowledge of
ase/control status (and consequently no recall or ascertainment
ias may  have played a role).
In Italy, inﬂuenza vaccination remains an unmet prior-
ty, as only 4% of children were vaccinated in the recent
easons [23]. Efforts should focus on paediatricians to dis-
uss the importance of inﬂuenza vaccination for preventing
ajor complications in both at-risk and healthy children. Sys-
ematic reviews and meta-analysis of existing studies may
rovide the basis for a new awareness on the positive beneﬁt-
isk proﬁle of the inﬂuenza vaccination even among healthy
hildren.
Our study provides additional data on the effectiveness of the
easonal inﬂuenza vaccination in preventing visits to the Emer-
ency Departments and hospitalisations for ILI, and adds further
vidence for vaccination recommendations especially in children.
unding
The study was  partially funded by the Italian Medicines Agency
AIFA).
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